Trial Profile
5-HT2A-receptor binding: implications for the pathophysiology of schizophrenia and effects of treatment with antipsychotic drugs.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 03 Nov 2021
Price :
$35
*
At a glance
- Drugs Quetiapine (Primary)
- Indications Schizophrenia
- Focus Pharmacodynamics
- 16 Sep 2011 Actual end date (Sep 2008) added as reported by ClinicalTrials.gov.
- 16 Sep 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 28 Nov 2007 Status changed from recruiting to in progress.